

Re-run

#12



RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/724,319

DATE: 01/06/2003

TIME: 12:49:58

Input Set : N:\Crf3\RULE60\09724319.raw
 Output Set: N:\CRF4\01062003\I724319.raw

1 <110> APPLICANT: Schenk, Dale B.
 2 Neuralab Limited
 3 <120> TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
 4 <130> FILE REFERENCE: 15270J-004740US
 6 <140> CURRENT APPLICATION NUMBER: 09/724,319
 7 <141> CURRENT FILING DATE: 2000-11-27
 9 <150> PRIOR APPLICATION NUMBER: US/09/322,289
 10 <151> PRIOR FILING DATE: 1999-05-28
 12 <160> NUMBER OF SEQ ID NOS: 5
 13 <170> SOFTWARE: PatentIn Ver. 2.1
 15 <210> SEQ ID NO: 1
 16 <211> LENGTH: 42
 17 <212> TYPE: PRT
 18 <213> ORGANISM: Homo sapiens
 19 <220> FEATURE:
 20 <223> OTHER INFORMATION: human Abeta42 beta-amyloid peptide
 21 <400> SEQUENCE: 1
 22 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
 23 1 5 10 15
 24 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
 25 20 25 30
 26 Gly Leu Met Val Gly Gly Val Val Ile Ala
 27 35 40
 29 <210> SEQ ID NO: 2
 30 <211> LENGTH: 13
 31 <212> TYPE: PRT
 32 <213> ORGANISM: Artificial Sequence
 33 <220> FEATURE:
 34 <223> OTHER INFORMATION: Description of Artificial Sequence:Abetal-12
 35 peptide with carboxyl terminal Cys residue
 36 inserted
 37 <400> SEQUENCE: 2
 38 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Cys
 39 1 5 10
 41 <210> SEQ ID NO: 3
 42 <211> LENGTH: 6
 43 <212> TYPE: PRT
 44 <213> ORGANISM: Artificial Sequence
 45 <220> FEATURE:
 46 <223> OTHER INFORMATION: Description of Artificial Sequence:Abetal-5
 47 peptide with carboxyl terminal Cys residue
 48 inserted
 49 <400> SEQUENCE: 3

ENTERED**BEST AVAILABLE COPY**

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/724,319

DATE: 01/06/2003

TIME: 12:49:58

Input Set : N:\Crf3\RULE60\09724319.raw
Output Set: N:\CRF4\01062003\I724319.raw

50 Asp Ala Glu Phe Arg Cys
51 1 5
53 <210> SEQ ID NO: 4
54 <211> LENGTH: 12
55 <212> TYPE: PRT
56 <213> ORGANISM: Artificial Sequence
57 <220> FEATURE:
58 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta33-42
59 peptide with carboxyl terminal Cys residue
60 inserted
W--> 61 <221> NAME/KEY: MOD_RES
62 <222> LOCATION: (2)
63 <223> OTHER INFORMATION: Xaa = amino heptanoic acid
W--> 64 <400> 4
W--> 65 Cys Xaa Gly Leu Met Val Gly Gly Val Val Ile Ala
66 1 5 10
68 <210> SEQ ID NO: 5
69 <211> LENGTH: 19
70 <212> TYPE: PRT
71 <213> ORGANISM: Artificial Sequence
72 <220> FEATURE:
73 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta13-28
74 peptide with carboxyl terminal Cys residue
75 inserted and two added Gly residues
W--> 76 <221> NAME/KEY: MOD_RES
77 <222> LOCATION: (1)
78 <223> OTHER INFORMATION: Xaa = acetyl histidine
W--> 79 <400> 5
W--> 80 Xaa His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
81 1 5 10 15
82 Gly Gly Cys

BEST AVAILABLE COPY

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/724,319

DATE: 01/06/2003
TIME: 12:49:59

Input Set : N:\Crf3\RULE60\09724319.raw
Output Set: N:\CRF4\01062003\I724319.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:4; Xaa Pos. 2
Seq#:5; Xaa Pos. 1

BEST AVAILABLE COPY

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/724,319

DATE: 01/06/2003
TIME: 12:49:59

Input Set : N:\Crf3\RULE60\09724319.raw
Output Set: N:\CRF4\01062003\I724319.raw

L:61 M:281 W: Numeric Fields not Ordered, <221> Sort in ascending order!
L:64 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:4
L:65 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:0
L:76 M:281 W: Numeric Fields not Ordered, <221> Sort in ascending order!
L:79 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:5
L:80 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:0

BEST AVAILABLE COPY